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Background: Management of renal cell carcinoma (RCC) with tumor thrombus extending to the renal vein and
inferior vena cava (IVC) is challenging. The aim of this study was to evaluate the benefit of surgical management in
such patients.
Methods: From February 1995 to February 2013, 520 patients were treated for RCC at Hirosaki University Hospital,
Hirosaki, Japan. The RCC patients with tumor thrombus extending to the renal vein (n = 42) and IVC (n = 43) were
included in this study. The records of these 85 patients were retrospectively reviewed to assess the relevant clinical
and pathological variables and survival. Prognostic factors were identified by multivariate analysis. The benefit of
surgical management was evaluated using propensity score matching to compare overall survival between patients
who received surgical management and those who did not.
Results: RCC was confirmed by pathological examination of surgical or biopsy specimens in 74 of the 85 patients
(87%). Sixty-five patients (76%) received surgical management (radical nephrectomy with thrombectomy). Distant
metastasis was identified in 45 patients (53%). The proportion of patients with tumor thrombus level 0 (renal vein only),
I, II, III, and IV was 49%, 13%, 18%, 14%, and 5%, respectively. The estimated 5-year overall survival rate was 70% in
patients with thrombus extending to the renal vein and 23% in patients with thrombus extending to the IVC.
Multivariate analysis identified thrombus extending to the IVC, presence of distant metastasis, surgical management,
serum albumin concentration, serum choline esterase concentration, neutrophil-lymphocyte ratio, and Carlson
comorbidity index as independent prognostic factors. In propensity score-matched patients, overall survival was
significantly longer in those who received surgical management than those who did not.
Conclusions: Surgical management may improve the prognosis of RCC patients with thrombus extending to the renal
vein and IVC.
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Figure 1 Classification of tumor thrombus level according to
the Mayo staging system. Level 0, thrombus extending to the
renal vein; level I, thrombus extending into the IVC to no more than
2 cm above the renal vein; level II, thrombus extending into the IVC
to more than 2 cm above the renal vein but not to the hepatic vein;
level III, thrombus extending into the IVC to above the hepatic vein
but not to the diaphragm; and level IV, thrombus extending into the
supradiaphragmatic IVC or right atrium.
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In renal cell carcinoma (RCC), thrombus extends to
the inferior vena cava (IVC) in 4–15% of patients [1,2].
With recent advances in surgical techniques and instru-
ments, radical nephrectomy with thrombectomy has been
reported to improve the prognosis of RCC patients without
distant metastasis [3]. However, surgery carries significant
risks of perioperative morbidity and mortality [4]. Previous
studies reported perioperative mortality rates of 0.1% for
general surgery patients overall and 5–10% for patients
undergoing radical nephrectomy with IVC thrombectomy
[5-7]. Although several studies reported large series of
RCC patients who underwent radical nephrectomy with
thrombectomy [8-10], only a few studies compared out-
comes between patients who underwent surgery and
those who did not [8,11]. The role of nephrectomy with
thrombectomy in patients with distant metastasis also
remains unclear. In this study of RCC patients with
renal vein and IVC thrombus, we compared outcomes
between patients who received surgical management and
those who did not.
Methods
Patients and staging
This study was performed in accordance with the ethical
standards of the Declaration of Helsinki. The study
protocol was approved by the institutional review board of
Hirosaki University School of Medicine. A total of 520
RCC patients were treated in our clinic from February
1995 to February 2013. Of these, 42 patients had tumor
thrombus extending to the renal vein (RV thrombus group)
and 43 had tumor thrombus extending to the IVC
(IVC thrombus group). The records of these 85 patients
were retrospectively reviewed to assess the relevant clinical
and pathological variables and survival.
All 85 patients underwent routine preoperative blood
tests; brain, chest, and abdominal computed tomography
(CT); abdominal magnetic resonance imaging; and/or bone
scintigraphy. Gross extension of tumor thrombus into the
venous system was detected by preoperative radiological
examinations, including contrast-enhanced CT, magnetic
resonance imaging, and/or vena cavography.
The level of tumor thrombus was determined according
to the Mayo classification (Figure 1): level 0, thrombus
extending to the renal vein only; level I, thrombus
extending into the IVC to no more than 2 cm above
the renal vein; level II, thrombus extending into the
IVC to more than 2 cm above the renal vein but not to the
hepatic vein; level III, thrombus extending into the IVC to
above the hepatic vein but not to the diaphragm; and level
IV, thrombus extending into the supradiaphragmatic
IVC or right atrium [12]. Pathological diagnoses were deter-
mined according to the 2009 Union for International
Cancer Control/American Joint Committee on CancerTNM system [13,14]. Overall patient condition was
assessed using the Eastern Cooperative Oncology Group
performance status (ECOG-PS) [15].
The basic treatment strategy for RCC with tumor
thrombus was surgical extirpation of the tumor, with
the aim of prolonging survival. Patients received non-
surgical management if they refused surgery or if they
had worsening systemic comorbidities, ECOG-PS >3,
extremely advanced metastatic disease that would be
difficult to control, or severe complications.
Surgical management
All patients who received surgical management underwent
radical nephrectomy, thrombectomy, and lymph node
dissection. Surgery was performed via a flank or midline
abdominal incision, depending on surgeon preference and
the characteristics of the tumor and associated thrombus.
In patients with supradiaphragmatic IVC thrombus, the
liver was mobilized to expose the retrohepatic vena cava by
incision of the falciform, triangular, and coronary ligaments,
in cooperation with the Department of Gastroenterological
Surgery. In patients with right atrium thrombus, sternotomy
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were performed in cooperation with the Department of
Cardiothoracic Surgery.
Follow-up schedule
Patients were evaluated for postoperative recurrence and
general condition by blood count, blood biochemistry
analysis, and chest and abdominal CT every 3 months for
the first year, and every 6 months thereafter. Chest CT was
used instead of chest X-ray in consideration of the relative
risks and benefits of these examinations. Brain CT was
performed when any new metastatic lesions or neurological
symptoms were observed. Patients did not receive routine
postoperative adjuvant therapy, but additional treatment
was given when new metastatic lesions were identified.
Statistical analysis
Patients in the RV thrombus group and IVC thrombus
group were analyzed separately. To evaluate the benefit
of surgical management, we compared overall survival
between propensity score-matched patients (difference
in score ≤0.03) who received surgical management and
those who did not. Propensity scores were calculated
by logistic analysis using conventionally recognized risk
factors for survival at the time of the initial visit, including
age, sex, ECOG-PS, level of tumor thrombus, presence of
distant metastasis, and Charlson comorbidity index.
Survival was calculated using the Kaplan–Meier method.
The significance of differences between groups was evalu-
ated using the log-rank test. Variables were compared be-
tween groups using the Student’s t-test or Mann–Whitney
U test. Prognostic factors were identified by univariate and
multivariate analyses using the Cox proportional hazards
model, and hazard ratios (HRs) with 95% confidence
intervals were calculated. All statistical analyses were
performed using the SPSS software package version 19.0
(SPSS, Chicago, IL, USA) and GraphPad Prism version
5.03 (GraphPad Software, San Diego, CA, USA). A value
of P < 0.05 was considered statistically significant.
Results
Patient characteristics are shown in Table 1 and overall
survival is shown in Figure 2. The diagnosis of RCC was
confirmed by pathological examination of surgical or
biopsy specimens in 74/85 patients (87%) and by im-
aging examination findings in 11 patients (13%). Forty-
two patients (49%) had thrombus extending to the
renal vein and 43 (51%) had thrombus extending to the
IVC. In patients with IVC thrombus, the thrombus was
classified as level I, II, III, and IV in 11 patients (13%),
15 patients (18%), 12 patients (14%), and 5 patients
(6%), respectively. The prevalence of multiple organ
metastases in surgical and non-surgical treatment group
was 6% and 57% in renal vein, 14% and 50% in level I, 15%and 100% in level II, 25% and 50% in level III, 0% and 67%
in level IV, respectively.
Sixty-five patients (76%) underwent radical nephrectomy
with thrombectomy, and 20 did not receive surgical
management. None of the patients who received surgi-
cal management underwent preoperative renal artery
embolization. The median follow-up period was 26 months
in patients who received surgical management and
5 months in patients who did not. Among the patients
who did not receive surgical management, eight received
immunotherapy or interferon-α 6,000,000 IU three
times/week, seven received molecular targeted therapy,
one underwent tumor embolization, and four received
best supportive care only. The reason for non-surgical
management was multiple organ or unresectable me-
tastasis in 14 patients (lung and lymph nodes, n = 6;
lung and bone, n = 2; lung, n = 2; lung, bone, and brain,
n = 1; lung and liver in a patient with duodenal invasion,
n = 1; brain, n = 1; lymph nodes, n = 1), patient refusal in 4
patients, dementia in 1 patient, and ECOG-PS >3 in 1
patient. In the whole group of 85 patients, the estimated
median overall survival time was 41 months and the es-
timated 5-year overall survival rate was 40% (Figure 3A,
Table 2). At the time of this report, 43 patients (51%)
had died of their disease, including 24 (43%) who received
surgical management and 15 (75%) who did not (P = 0.003).
In all patients who did not receive surgical management,
the main cause of death was cachexia. In patients who re-
ceived surgical management, the estimated median survival
time was 60 months and the estimated 5-year overall
survival rate was 54%. In patients who did not receive sur-
gical management, the estimated median survival time
was 8.2 months and the estimated 5-year survival rate was
0% (Table 2). Distant metastasis was present at the time of
diagnosis in 45 patients (53%). In patients with distant me-
tastasis at presentation, the median overall survival time
was 11 months and the estimated 5-year survival rate was
21%. In patients without distant metastasis at presenta-
tion, the estimated median survival time was 24 months
and the estimated 5-year survival rate was 80% (Table 2).
The independent prognostic factors identified by multi-
variate analysis using the Cox proportional hazards model
were thrombus level, presence of distant metastasis, sur-
gical management, serum albumin concentration, serum
choline esterase concentration, neutrophil-lymphocyte
ratio, and Charlson comorbidity index (Table 3).
RCC patients with tumor thrombus extending to the
renal vein
Thirty-five of the 42 patients in the RV thrombus group
received surgical management and 7 did not. None of these
patients underwent metastasectomy, except for lymph node
dissection. There were no significant differences between
patients who received surgical management and those who
Table 1 Patient characteristics








n 85 35 7 30 13
Age* 62 ± 12 63 ± 10 62 ± 10 0.790 59 ± 14 37 ± 11 0.078
Gender 24/11 4/3 0.558 17/13 10/3 0.021
ECOG-PS 0.6 ± 1.1 0.3 ± 0.7 0.7 ± 1.5 0.484 0.5 ± 1.0 1.6 ± 1.4 0.021
Radical surgery 65(76%) 35 0 30 0
Perioperative morality within 1 month 0(0%) 2(7%)
Thrombus level
Renal vein 42(49%) 35 7
I 11(13%) 7(23%) 4(31%)
0.203
II 15(18%) 13(43%) 2(15%)
III 12(14%) 8(27%) 4(31%)
IV 5(6%) 2(7%) 3(23%)
Clinical TNM




cT4 7(8%) 0(0%) 1(14%) 0(0%) 6(46%)
cN+ 20(24%) 1(3%) 5(71%) <0.0001 5(17%) 9(69%) 0.001
cM+ 45(53%) 11(31%) 6(86%) 0.008 17(33%) 11(85%) 0.041
Multiple organ metastasis 19(22%) 2(6%) 4(57%) 0.006 5(17%) 8(62%) 0.041
Thrombus level (I/II/III/IV) 1/2/2/0 2/2/2/2
Histology
Clear 67(79%) 31(89%) 5(71%)
0.426
27(93%) 4(31%)
0.508Others 7(8%) 4(11%) 0(0%) 3(7%) 0(0%)
Unknown 11(13%) 0(0%) 2(29%) 0(0%) 9(96%)
Grade
G1/2 43(51%) 25(71%) 0(0%)
0.002
12(40%) 4(31%)
0.024G3 31(36%) 10(29%) 5(71%) 12(40%) 4(31%)
Unknown 11(13%) 0(0%) 2(29%) 0(0%) 9(69%)
Hemoglobin (g/dl)* 11.6 ± 2.4 12.0 ± 2.2 104 ± 2.0 0.081 11.4 ± 2.3 11.2 ± 3.3 0.752
Neutrophil-lymphocyte ratio* 3.1 ± 1.5 2.8 ± 1.2 3.6 ± 1.2 0.156 3.1 ± 1.9 3.6 ± 1.5 0.402
Serum albumin (g/dl)* 3.8 ± 0.6 3.9 ± 0.6 3.4 ± 0.8 0.122 3.9 ± 0.6 3.5 ± 1.5 0.080
Renal function (ml/min./1.73 m2)* 63 ± 23 71 ± 20 52 ± 21 0.063 60 ± 23 56 ± 25 0.605
Lactate dehydrogenase (LDH,|IU/L)* 214 ± 112 185 ± 45 304 ± 217 0.198 199 ± 80 274 ± 172 0.154
Choline esterase (U/L)* 224 ± 105 248 ± 98 234 ± 72 0.665 215 ± 130 172 ± 102 0.252
Serum sodium (mEq/L)* 141 ± 2.5 142 ± 2.3 139 ± 3.7 0.111 142 ± 2.2 139 ± 2.3 0.005
Correlated calcium (mg/dL)* 9.6 ± 0.8 9.4 ± 0.6 9.9 ± 0.8 0.153 9.6 ± 0.8 10.1 ± 0.8 0.069
C-reactive protein (CRP, mg/dL)* 4.4 ± 5.4 4.1 ± 6.1 4.8 ± 3.3 0.648 3.7 ± 6.0 6.4 ± 4.6 0.125
Charlson comorbidity index* 7.7 ± 3.4 6.6 ± 3.1 11.3 ± 1.6 <0.0001 7.2 ± 3.1 10.3 ± 3.0 0.004
Molecular targeted agents 18(21%) 5(14%) 4(57%) 0.012 6(20%) 3(23%) 0.549
Deceased 43(51%) 8(23%) 4(57%) 0.067 20(67%) 11(85%) 0.228
*Mean ± SD.






















Figure 2 Management of enrolled patients. A total of 85 patients
were enrolled in this study, including 42 in the RV group and 43 in
the IVC group. Sixty-five patients underwent radical nephrectomy
with thrombectomy and 20 did not undergo surgery.
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and blood biochemistry data. However, there were sig-
nificant differences between these two groups in clinical
T stage, lymph node involvement, presence of distant
metastasis, tumor grade, Charlson comorbidity index,
and administration of molecular targeted agents. In patientsFigure 3 Survival in the RV and IVC thrombus groups, according to su
the RV thrombus and IVC thrombus groups. (B) In the RV thrombus group,
management than those who did not. (C) In the RV thrombus group, dista
thrombus group, thrombus level was not significantly correlated with over
longer in patients who received surgical management than those who did
significant prognostic factor.who received surgical management, the median blood loss
was 744 g (range 10–3,221 g). Five patients with blood
loss >1,500 g received blood transfusions. Two patients
(6%) developed perioperative complications of Clavien
grade ≥ III, and there were no deaths within 1 month of
surgery. No patients required cardiopulmonary bypass
during surgery. In the whole RV thrombus group, the
estimated median survival time was “undefined”, and
the estimated 5-year survival rate was 70%. In patients
who received surgical management, the estimated median
survival time was “undefined” and the estimated 5-year
survival rate was 78%. In patients who did not receive
surgical management, the estimated median survival time
was 4.9 months and the estimated 5-year survival rate was
0% (Figure 3B, Table 2). In patients with distant metastasis
at presentation, the estimated median survival time was
26 months and the estimated 5-year survival rate was 42%.
In patients without distant metastasis at presentation, the
estimated median survival time was “undefined” and the es-
timated 5-year survival rate was 90% (Figure 3C, Table 2).
The independent prognostic factors identified by multi-
variate analysis using the Cox proportional hazards model
in the RV thrombus group were presence of distantrgical management and distant metastasis. (A) Overall survival in
survival was significantly longer in patients who received surgical
nt metastasis was a powerful prognostic factor. (D) In the IVC
all survival. (E) In the IVC thrombus group, survival was significantly
not. (F) In the IVC thrombus group, distant metastasis was not a
Table 2 Estimated median overall survival times and 5-year overall survival rates
All patients Surgery group Non-surgery group Without metastasis With metastasis
Median survival (M) 41 60 8.2 24 11
5-year survival (%) 40 54 0 80 21
RV thrombus
Median survival (M) Undefined Undefined 49 Undefined 26
5-year survival (%) 70 78 0 90 42
IVC thrombus
Median survival (M) 24 29 5.1 68 17
5-year survival (%) 23 32 0 54 12
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agement was not an independent prognostic factor in
this group (Table 3).
RCC patients with tumor thrombus extending to the IVC
Thirty of the 43 patients in the IVC thrombus group
received surgical management and 13 did not. Ten of
these patients underwent metastasectomy (adrenal, n = 1;
bone, n = 1; lymph nodes, n = 2; liver, n = 1; liver, n = 2;
IVC, n = 4) at the time of radical nephrectomy with
thrombectomy. Four of these patients had positive surgical
tumor margins, and these four all died within 3 years of
surgery (median overall survival time: 26 months). There
were significant differences between patients who received
surgical management and those who did not in ECOG-PS,
clinical T stage, lymph node involvement, tumor grade,
serum sodium concentration, and Charlson comorbidity
index. Other factors, including presence of distant metasta-
sis, did not differ significantly between these two groups. In
patients with thrombus level I, II, and III/IV who received
surgical management, the median blood loss was 620 g
(range 80–953 g), 1,255 g (range 810–5,100 g), and 3,397 g
(range 2,454–13,800 g), respectively. Eighteen patients
underwent blood transfusion because of blood loss >1,000 g
or hypotension. Cardiopulmonary bypass was performed in
three patients. Eight patients (19%) developed perioperative
complications of Clavien grade ≥ III and two patients (6.7%)
died within 1 month of surgery. There was no correlation
between the level of IVC tumor thrombus and overall
survival (Figure 3D). In the whole IVC thrombus group,
the estimated median survival time was 24 months and
the estimated 5-year survival rate was 23%. In patients
who received surgical management, the estimated median
survival time was 29 months and the estimated 5-year
survival rate was 32%. In patients who did not receive
surgical management, the estimated median survival
time was 5.1 months and the estimated 5-year survival
rate was 0% (Figure 3E, Table 2). In patients with distant
metastasis at presentation, the estimated median survival
time was 17 months and the estimated 5-year survival
rate was 12%. In patients without distant metastasis atpresentation, the estimated median survival time was
“undefined” and the estimated 5-year survival rate was
90% (Figure 3F, Table 2). The independent prognostic
factors identified by multivariate analysis using the
Cox proportional hazards model in the IVC thrombus
group were surgical management, serum albumin con-
centration, adjusted serum calcium concentration, and
neutrophil-lymphocyte ratio (Table 3).
Propensity score-matched analysis
Propensity score-matched analysis was used to compare
overall survival between patients who received surgical
management and those who did not. Conventionally
recognized risk factors for survival including age, sex,
ECOG-PS, level of tumor thrombus, presence of distant
metastasis, and Charlson comorbidity index were con-
trolled for using logistic analysis. Thirty pair-matched
patients (15 patients who received surgical management
and 15 who did not) were selected for analysis. The
characteristics of these 30 patients are shown in Table 4.
The only significant difference between patients who
received surgical management and those who did not,
including both matched and unmatched variables, was
in serum sodium concentration.
Among propensity score-matched patients, the overall
survival time was significantly longer in those who received
surgical management than those who did not. In patients
who received surgical management, the estimated median
survival time was 29 months and the estimated 5-year
survival rate was 20%. In patients who did not receive
surgical management, the estimated median survival
time was 7 months and the estimated 5-year survival
rate was 0% (Figure 4).
Discussion
Aggressive surgical management with a hope of cure is
currently the standard treatment for RCC patients with
tumor thrombus extending to the RV and IVC, even
though such surgery is challenging. In this study, the
perioperative mortality rate in patients with IVC thrombus
was 6.7%, which is significantly higher than the overall
Table 3 Univariate and multivariate analyses for overall survival
All RV thrombus group IVC thrombus group
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Independent factors P value HR 95.0% CI P value HR 95.0% CI P value HR 95.0% CI P value HR 95.0% CI P value HR 95.0% CI P value HR 95.0% CI
Age 0.875 0.997 0.972-1.024 0.645 1.013 0.958-1.072 0.877 1.002 0.974-1.032
ECOG-Performance status 0.002 1.433 1.151-1.869 0.045 1.776 1.012-3.115 0.063 1.297 0.986-1.704
Gender (ref, female) 0.073 0.576 1.315-1.053 0.018 0.234 0.070-0.776 0.086 0.860 0.414-1.787
Thrombus level
(ref, renal vein)
0.000 1.472 1.185-1.830 0.034 1.275 1.0181.599 0.179 1.315 0.882-1.960
Distant metastasis
(ref, without metastasis)
0.000 4.115 2.020-8.384 0.019 2.548 1.168-5.560 0.003 9.673 2.113-44.27 0.000 34.01 5.368-215.6 0.094 1.996 0.888-4.4483
Underwent surgery
(ref, not performed)
0.000 0.144 0.069-0.303 0.000 0.239 0.108-0.532 0.008 0.180 0.051-0.636 0.000 0.105 0.036-0.305 0.000 0.061 0.016-0.230
Hemoglobin (g/dL) 0.002 0.807 0.704-0.926 0.005 0.645 0.477-0.873 0.002 0.500 0.323-0.775 0.056 0.863 0.742-1.004
Serum albumin (g/dL) 0.003 0.487 0.306-0.778 0.026 0.849 0.736-0.980 0.124 0.537 0.244-1.186 0.004 0.408 0.221-0.756 0.002 0.250 0.104-0.600
eGFR (ml/min./1.73 m2) 0.190 0.989 0.974-1.005 0.470 0.989 0.961-1.019 0.494 0.999 0.995-1.002
Choline esterase (U/L) 0.052 0.996 0.994-1.000 0.023 0.995 0.992-0.999 0.156 0.996 0.991-1.002 0.002 1.407 1.137-1.740 0.053 1.282 0.996-1.648
Neutrophil-lymphocyte
ratio
0.007 1.297 1.072-1.571 0.021 1.250 1.034-1.513 0.387 1.204 0.791-1.835 0.002 1.407 1.137-1.740 0.053 1.282 0.993-1.648
Serum sodium (mEq/L) 0.001 0.814 0.721-0.921 0.006 0.774 0.644-0.931 0.090 0.862 0.723-1.023
Correlated calcium
(mg/dL)
0.322 1.143 0.877-1.491 0.109 1.982 0.858-4.579 0.439 0.854 0.572-1.274 0.038 0.598 0.368-0.973
Lactate dehydrogenase
(LDH, IU/L)
0.000 1.004 1.002-1.006 0.071 1.004 1.001-1.008 0.019 1.003 1.001-1.006
C-reactive protein
(CRP, mg/dL)
0.044 1.046 1.001-1.093 0.032 1.083 1.007-1.165 0.299 1.029 0.975-1.0865
Charlson comorbidity
index
0.000 1.258 1.130-1.401 0.006 1.196 1.053-1.360 0.002 1.442 1.144-1.818 0.022 1.152 1.020-1.3007
Molecular targeted
agents (ref, not used)




















Table 4 Characteristics of the patients included in the propensity score-matched analysis
Propensity score matched patients Surgery performed Surgery not performed P value
<Matched parameters>
n 15 15
Age* 63 ± 11 63 ± 11 0.923
Gender (male/female) 9/6 9/6 1.000
ECOG-PS* 0.7 ± 1.2 0.9 ± 1.1 0.758
Presence of distant metastasis (M+) 13 (87%) 12 (80%) 0.624
Thrombus level 0.624







cT3 15 (100%) 12 (80%)
0.068
cT4 0 (0%) 3 (20%)
cN+ 5 (33%) 10 (66%) 0.068
Hemoglobin (g/dL)* 11 ± 2.4 11 ± 3.2 0.857
Neutrophil-lymphocyte ratio* 3.2 ± 1.5 3.5 ± 1.2 0.636
Serum albumin (g/dL)* 3.8 ± 0.5 3.6 ± 0.6 0.331
Renal function (ml/min./1.73 m2)* 60 ± 16 58 ± 20 0.756
Lactate dehydrogenase (LDH, IU/L)* 200 ± 57 279 ± 201 0.160
Choline esterase (U/L)* 240 ± 110 188 ± 107 0.213
Serum sodium (mEq/L)* 141 ± 1.9 139 ± 3.0 0.028
Correlated Calcium (mg/dL)* 9.9 ± 1.0 9.9 ± 0.7 0.977
C-reactive protein (CRP, mg/dL)* 6.0 ± 7.3 5.3 ± 4.6 0.787
Charlson comorbidity index* 10 ± 1.5 10 ± 2.5 0.864
Molecular targeted argents 6 (40%) 6 (40%) 1.000
Deceased 10 (67%) 11 (73%) 0.690
*(Mean ± SD).
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undergo urological surgery at our institute. Although
many studies reported benefits associated with surgical
management in RCC patients with tumor thrombus
extending to the RV and IVC [10,16-18], only a few studies
compared outcomes between patients who underwent
surgery and those who did not [8,11]. No randomized
studies assessing the benefits of surgical management
in RCC patients with a poor prognosis have been reported,
because the decisions regarding surgical management
of these patients depend on factors such as performance
status, severe comorbidities, and the presence of metastasis.
The largest reported series of RCC patients with renal vein
and IVC thrombus, which included 1,122 patients with a
median follow-up period of 24.7 months, found a median
overall survival time of 33.8 months [19]. However, the roleof surgical management in that series is unclear because
outcomes were not compared between RCC patients with
tumor thrombus who underwent surgery and those who
did not. In this study, we used propensity score-matched
analysis to retrospectively compare outcomes between RCC
patients with renal vein and IVC thrombus who received
surgical management and those who did not.
In all 85 patients studied, the following factors were
identified as independent predictors of overall survival:
thrombus level, presence of distant metastasis, surgical
management, serum albumin concentration, serum choline
esterase concentration, neutrophil-lymphocyte ratio, and
Charlson comorbidity index.
This study found that patients who underwent radical
nephrectomy with thrombectomy survived longer than
those who received non-surgical management. However,






















Figure 4 Overall survival curves, estimated median survival
times, and estimated 5-year survival rates in pair-matched
patients. Comparison of the 15 pairs of propensity score-matched
patients suggests that surgical management may improve survival.
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bias and the significant differences in variables between
patients who received surgical management and those who
did not. Patients who did not receive surgical manage-
ment had a higher ECOG-PS and greater tumor burden,
including unresectable disease and metastasis. The median
survival times in patients who received surgical manage-
ment and those who did not are comparable with those
previously reported [8,11,18].
In the RV thrombus group, most patients (83%) received
surgical management. Patients with thrombus that does
not extend beyond the renal vein are more likely to have
organ-confined disease and to be surgical candidates than
patients with IVC thrombus. There were no significant
differences between patients with thrombus extending
to the renal vein who received surgical management and
those who did not in terms of age and ECOG-PS, but there
were significant differences between these two groups in
organ-confined disease, presence of distant metastasis,
tumor grade, Charlson comorbidity index, and adminis-
tration of targeting agents. These findings suggest that
RCC patients with more advanced disease were less likely
to receive surgical management. The estimated median
survival time was significantly longer in patients who
received surgical management than in those who did not
(“undefined” vs. 4.9 months). The estimated median
survival times in this study are comparable with those
previously reported [8,10]. Multivariate analysis of the RV
thrombus group identified presence of distant metastasis
and hemoglobin concentration as independent prognostic
factors for overall survival. The estimated 5-year survival
rate was 90% in patients with distant metastasis and 42%
in patients without distant metastasis.In the IVC thrombus group, 70% of patients received
surgical management. There were no significant differences
between patients who received surgical management
and those who did not in terms of age, thrombus level,
or presence of distant metastasis, but there were significant
differences between these two groups in ECOG-PS, clinical
T stage, clinical N stage, tumor grade, serum sodium
concentration, and Charlson comorbidity index. These
findings suggest that patients with advanced RCC and
poor general status were more likely to receive non-
surgical management. As in the RV thrombus group,
the estimated median survival time was significantly
longer in patients who received surgical management
than those who did not (29 vs. 5.1 months, P < 0.0001). The
estimated median survival times in this study are com-
parable with those previously reported [8,10,11,18].
Multivariate analysis of the IVC thrombus group identi-
fied surgical management, serum albumin concentration,
neutrophil-lymphocyte ratio, and adjusted serum calcium
concentration as independent prognostic factors for
overall survival; but not thrombus level or presence of
distant metastasis. The relationship between the level
of IVC thrombus and prognosis is currently unclear
[10,19-21]. Kim et al. reported that the level of tumor
thrombus was not a predictor of cancer-specific survival on
multivariate analysis (HR 0.95, P = 0.872) [20]. In contrast,
Martinez-Salamanca et al. reported that tumor thrombus
extending above the diaphragm (HR 2.10, P = 0.00), tumor
diameter >7 cm, Furman grade, fat invasion, lymph
node metastasis, and presence of distant metastasis were
independent predictors of cancer-specific survival [19]. In
this study, thrombus level of IVC was not identified as a
significant predictor of overall survival. There was also no
significant difference in overall survival between pa-
tients with suprahepatic IVC thrombus and those with
infrahepatic IVC thrombus only (data not shown). This
lack of association between thrombus level and survival
may be due to the relatively small sample size.
The presence of distant metastasis has been reported
to be a very powerful prognostic factor in RCC patients
with tumor thrombus [10]. Lambert et al. studied RCC
patients with venous tumor thrombus, and found a 5-year
cancer-specific survival rate of 10.0% in patients with
distant metastasis and 60.3% in those without distant
metastasis [22]. Although the presence of distant metasta-
sis was not identified as an independent prognostic factor
in this study, the estimated 5-year overall survival rate was
significantly lower in patients with distant metastasis than
those without (12% vs. 54%, P = 0.0883).
We used propensity score-matched analysis to control
for patient characteristics when comparing overall survival
between patients who received surgical management
and those who did not. The variables used for the logistic
analysis were conventionally recognized risk factors for
Hatakeyama et al. BMC Urology 2013, 13:47 Page 10 of 11
http://www.biomedcentral.com/1471-2490/13/47survival, including age, sex, ECOG-PS, level of tumor
thrombus, presence of distant metastasis, and Charlson
comorbidity index. Table 4 shows the matched and
unmatched variables in patients who received surgical
management and those who did not. Comparison of the
15 pairs of propensity score-matched patients suggests
that surgical management may improve survival. The
estimated median survival time was four times longer in
patients who received surgical management than those
who did not (P = 0.0045).
The findings of this study and of previous studies
[3,8-10,17,18,23] suggest that the upper limit of the 5-year
survival rate in RCC patients with venous thrombus who
receive surgical management may be 50–60%. Because
these patients have a high rate of metastasis at presen-
tation, optimal systemic therapy, such as neoadjuvant
therapy using molecular-targeting agents, is important.
The first report of neoadjuvant sunitinib therapy in an
RCC patient with IVC thrombus described a significant
down-staging of the thrombus and reduction of the extent
of surgery required [24]. Subsequent studies reported
significant reduction in tumor thrombus after preoperative
sunitinib [25] or sorafenib therapy [16]. These data suggest
that neoadjuvant therapy can downsize thrombus with
minimal invasiveness, thereby increasing surgical resectabil-
ity. However, some studies did not report good results after
neoadjuvant therapy [23,26]. In 2011, Cost et al. reported
that targeted therapy resulted in only a 12% cytoreductive
effect and a high rate of progression. The usefulness of
neoadjuvant targeted therapy therefore remains unclear.
This study has several limitations, including the small
sample size and the inclusion of only patients treated at
a single institution. These factors make it difficult to con-
trol for selection bias and patient characteristics. However,
an advantage of this study is the use of propensity
score matching between patients who received surgical
management and those who did not. The results show
an overall survival benefit for patients who received
surgical management. Randomized trials including lar-
ger numbers of patients from multiple institutions are
necessary to clarify the benefits of surgical management in
patients with RCC with venous thrombus.
Conclusions
Surgical management may improve the prognosis of
RCC patients with thrombus extending to the renal
vein and IVC.
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